The company’s co-founders said they are leaving to start a new mRNA-based company.

BioNTech (BNTX), the partner of Pfizer (PFE) for the Comirnaty COVID-19 vaccine, fell 18% in the premarket on Tuesday after its Q4 2025 financials, as its full-year outlook fell short of Street ...

COVID-19 vaccine recommendations could be changing, according to the U.S. Food and Drug Administration. FDA leaders said on May 20 that clinical trials will be required to approve annual COVID-19 ...

Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "Comirnaty (Tozinameran) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's ...

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...

PFE faces falling COVID sales, looming patent cliffs and IRA pressure. It is betting on cost cuts, new launches and pipeline rebuilds to revive growth.

The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed recommendations on who should get them. Approval of ...